Too small to fail.

This hypothesis-generating NCDB analysis suggests, in the rare instance pancreatic cancer is discovered while it’s still less than 1 cm (pT1a/b), there is no survival benefit with adjuvant chemo in the face of current NCCN guidelines. Sure, any survival analysis using the NCDB is fraught with bias. But this is intriguing considering the most obvious bias would place less healthy people in the no-chemo camp. | Shaib, Cancer 2018